 |
| | |
|
 |
|
Client Listing
Licensing and Corporate Partnerships
For Orchid BioSciences, Inc. (As COO and CFO of the Company)
| Company |
Date |
Type of Agreement |
Face Value1 |
| Sarnoff Corporation |
December '97 |
License (in), Collaboration and Option |
$36.0 Million |
| Motorola, Inc. |
March '98 |
License (out), Collaboration and Equity Investment |
$10.0 Million |
| Dynal A.S. |
April '98 |
License (in) and Supply |
$2.0 Million |
| Affymetrix, Inc. |
November '99 |
License (out/in), Collaboration and Equity Investment |
$10.0 Million |
| Perkin Elmer Corporation |
July '00
January '01 |
License (out), Supply and Equity Investment |
$5.0 Million |
| Amersham Pharmacia Biotech, Inc. |
June '00 |
License (out) |
2.0 Million |
| Applied BioSystems, Inc. |
July '00 |
License (out) |
$2.0 Million |
| AstraZeneca UK, Ltd. |
February '01 |
Collaboration and Supply |
$2.5 Million |
| Luminex Corporation |
May '00 |
License (in) and Supply |
$2.0 Million |
The SNP Consortium
(10 Big Pharma Companies) |
July '00 |
Collaboration and Supply |
$2.0 - $5.0 Million |
| Invitrogen Corporation |
November '01 |
License (out) and Supply |
$2.0 Million |
| Quest Diagnostics, Inc. |
December '01 |
License (out) |
$1.0 Million |
| Beckman-Coulter, Inc. |
January '02 |
License (out/in) |
$2.0 Million |
For IdentiGen Ltd. (As President and CEO of the Company)
| Company |
Date |
Type of Agreement |
Face Value1 |
| DSM Nutritional Products AG |
June '08 |
Service and License |
$2.0 Million |
For Tepnel Life Sciences PLC (As Financial Advisor to the Company)
| Company |
Date |
Type of Agreement |
Face Value1 |
| Boehringer Ingelheim Corp. |
December ‘04 |
Research Collaboration |
$5.0 Million |
1 Face value of transaction does not include value of royalty stream, where applicable.
|
|
